Can I stop taking Sotorasib once I start taking it?

Sotorasib is a targeted small molecule inhibitor targeting the KRAS G12C mutation. It is mainly used to treat patients with non-small cell lung cancer (NSCLC) who carry this gene mutation. As a precision targeted therapy drug, it blocks tumor cell proliferation signals by irreversibly inhibiting the activity of KRAS G12C protein, thereby delaying the progression of the disease. The drug showed good efficacy and tolerability in clinical trials.

Once a patient starts taking sotoraxib, indiscriminate discontinuation may lead to the reactivation of tumor growth signals and accelerate disease progression. In addition, sudden discontinuation of medication may increase the fluctuation of drug concentration in the body, causing side effects or instability of adverse reactions. Therefore, there is a higher risk of discontinuing medication without medical guidance, especially when the therapeutic effect has not yet been fully observed.

In clinical practice, if a patient experiences severe side effects or is unwell, the doctor may adjust the dosage or extend the medication interval based on the patient's condition rather than discontinuing the medication completely. This strategy of "reducing the dose or temporarily stopping the drug and then resuming it" helps to ensure the efficacy while reducing the risk of adverse reactions. Patients should follow physician recommendations and undergo regular hematology and imaging tests to evaluate efficacy and safety.

The key to the safe use of sotorasiib lies in standardized medication and close follow-up. Patients should maintain a regular schedule while taking the medication and avoid stopping the medication or changing the dose on their own; if they feel unwell, they should seek medical treatment in time. Regular review can help doctors judge the efficacy, adjust the treatment plan, and guide the safe discontinuation of medication or transition to other treatment plans when necessary, thereby achieving individualized, continuous and effective treatment management.

Reference link:https://www.drugs.com